In the present study, we used different αVβ3- and VEGFR2-positive ovarian carcinoma cell lines including drug-resistant variants to test the effects of conjugates 1–3 made by the covalent junction of a selective binder of the extracellular portion of integrin αVβ3 to the RTK inhibitor sunitinib. The gene discussed is KDR; the disease is ovarian carcinoma.